Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MoonLake Immunotherapeutics (MLTX : NSDQ)

• Company Description    MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON. Number of Employees: 100

• Price / Volume Information    Yesterday's Closing Price: $54.30 Daily Weekly Monthly 20 Day Moving Average: 575,855 shares Shares Outstanding: 64.23 (millions) Market Capitalization: $3,487.73 (millions) Beta: 1.27 52 Week High: $61.87 52 Week Low: $31.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.06% -2.84% 12 Week 24.83% 13.33% Year To Date 0.28% -10.47%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL DORFSTRASSE 29 - ZUG,V8 6300 CHE ph: 41-41-510-8022 fax: - ir@moonlaketx.com http://www.moonlaketx.com

• General Corporate Information    Officers Jorge Santos da Silva - Chief Executive Officer; Director Simon Sturge - Chairperson; Director Matthias Bodenstedt - Chief Financial Officer Spike Loy - Director Catherine Moukheibir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 61559X104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 64.23 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $3,487.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.74 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -123.08% vs. Previous Quarter: -38.10% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -40.98 03/31/25 - -30.81 12/31/24 - -23.52 ROA 06/30/25 - -35.81 03/31/25 - -28.40 12/31/24 - -22.69 Current Ratio 06/30/25 - 16.65 03/31/25 - 21.11 12/31/24 - 21.11 Quick Ratio 06/30/25 - 16.65 03/31/25 - 21.11 12/31/24 - 21.11 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 5.58 03/31/25 - 6.45 12/31/24 - 7.09 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.21 03/31/25 - 0.18 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 17.01 03/31/25 - 15.04 12/31/24 - 0.00

Powered by Zacks Investment Research ©